Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (6176)	10/24/2001 4:25:05 PM
From: BW	Read Replies (2) \| Respond to of 48461

Keep teeing 'em up Capt! I got into a little SURE yesterday, not too much though, I've got hardly any cash right now. Not one of your megga gains but my NTKK popped 70% today <g> I need to learn some more about trading options. A quick question, and it might be a silly one. Are you exercising you options or selling the premium to someone else? thanks as always Boyd

To: Bucky Katt who wrote (6176)	10/24/2001 5:28:06 PM
From: xcr600	Read Replies (1) \| Respond to of 48461

Stem cell plays have been pretty much forgotten about since Sept 11. Might be a good time to start accumulating a few shares for the future. Another thought, online etailers for Xmas this year. With paranoia sweeping the country online sales should boom as everyone is afraid to head for the malls. Some of the old dogs such as COOL, SATH, SPGLA, SHRP, etc..etc.. might offer some nice home runs.

To: Bucky Katt who wrote (6176)	10/25/2001 3:51:42 AM
From: BW	Read Replies (1) \| Respond to of 48461

New biohype rat - IBPI IntraBiotics Pharmaceuticals, Inc. develops and intends to commercialize novel antibacterial and anti-fungal drugs for the prevention or treatment of serious infectious diseases. The Company's clinical and development programs focus on solving medical problems for patients who have few or no satisfactory alternatives. Because of their bacteria- or fungi-killing mechanisms, the Company's drug candidates are designed to be useful in fighting microorganisms that are resistant to traditional antibiotics. Boyd